SANA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 105094 min ago

@ $7.22

Išleistas: 14 vas. 2024 @ 22:45

Grąža: 20.86%

Ankstesnis signalas: vas. 13 - 21:34

Ankstesnis signalas: Pardavimas

Grąža: 12.56 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	1.59M
Vidutinė apimtis	2.01M
Rinkos kapitalizacija	1.92B
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $-0.300 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.97
ATR14	$0.0150 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Bishop Hans Edgar	Buy	2 774	Common Stock
2024-04-01	Fmr Llc	Buy	0	Common Stock
2024-03-08	Yang Patrick Y	Sell	25 000	Common Stock
2024-03-07	Williams Douglas E	Buy	301 875	Stock Option (Right to Buy)
2024-03-07	Williams Douglas E	Buy	67 083	Restricted Stock Units

INSIDER POWER
6.22
Last 97 transactions
Buy: 15 455 910 \| Sell: 11 982 863

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: -0.29 (neutral)

Signal:(47.218) Neutral

Sana Biotechnology, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ALVR	0.839
MDVL	0.839
TCRT	0.836
USEG	0.834
HOOK	0.832
TLSA	0.832
GRAY	0.828
INFI	0.824
OPK	0.815
RUBY	0.815

10 Labiausiai neigiamai susiję koreliacijos
BNIXU	-0.875
MICT	-0.812

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sana Biotechnology, Inc. Koreliacija - Valiuta/Žaliavos

-0.50
( weak negative )

-0.21
( neutral )

0.00
( neutral )

-0.37
( neutral )

Sana Biotechnology, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2023
Pajamos:	$0
Bruto pelnas:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2022
Pajamos:	$0
Bruto pelnas:	$-27.73M (0.00 %)
EPS:	$-1.410

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.958

Financial Reports:

No articles found.

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.